PriceTargets.com logo

Evotec - EVT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€6.40 As of 04/17/2025 01:00 AM ET
▲ +0.576 (9.90%)

This chart shows the closing price for EVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evotec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVT

Analyst Price Target is €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Evotec in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €6.40.

This chart shows the closing price for EVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Evotec. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/29/2023Deutsche Bank AktiengesellschaftSet Target€21.00
3/28/2023Warburg ResearchSet Target€29.00
3/28/2023Royal Bank of CanadaSet Target€28.00
3/28/2023Jefferies Financial GroupSet Target€34.00
3/16/2023Royal Bank of CanadaSet Target€28.00
3/6/2023Deutsche Bank AktiengesellschaftSet Target€21.00
1/24/2023Warburg ResearchSet Target€29.00
12/19/2022Deutsche Bank AktiengesellschaftSet Target€21.00
11/28/2022Royal Bank of CanadaSet Target€28.00
11/16/2022Deutsche Bank AktiengesellschaftSet Target€21.00
11/9/2022Warburg ResearchSet Target€34.00
11/9/2022Jefferies Financial GroupSet Target€38.00
11/9/2022Royal Bank of CanadaSet Target€35.00
11/3/2022Royal Bank of CanadaSet Target€35.00
10/19/2022Deutsche Bank AktiengesellschaftSet Target€26.00
10/17/2022Jefferies Financial GroupSet Target€38.00
10/7/2022Royal Bank of CanadaSet Target€35.00
8/31/2022Deutsche Bank AktiengesellschaftSet Target€30.00
8/25/2022Deutsche Bank AktiengesellschaftSet Target€30.00
8/23/2022Royal Bank of CanadaSet Target€35.00
8/12/2022Deutsche Bank AktiengesellschaftSet Target€30.00
8/11/2022Warburg ResearchSet Target€38.00
8/10/2022Morgan StanleySet Target€32.00
8/5/2022Royal Bank of CanadaSet Target€43.00
6/29/2022Berenberg BankSet Target€47.00
5/31/2022Deutsche Bank AktiengesellschaftSet Target€30.00
5/24/2022Berenberg BankSet Target€47.00
5/18/2022Deutsche Bank AktiengesellschaftSet Target€30.00
5/17/2022Royal Bank of CanadaSet Target€43.00
5/16/2022Berenberg BankSet Target€47.00
5/12/2022Deutsche Bank AktiengesellschaftSet Target€33.00
5/11/2022Jefferies Financial GroupSet Target€45.00
5/11/2022Warburg ResearchSet Target€43.00
5/10/2022Royal Bank of CanadaSet Target€43.00
4/29/2022Morgan StanleySet Target€42.00
4/22/2022Warburg ResearchSet Target€43.00
4/20/2022Berenberg BankSet Target€47.00
4/19/2022Deutsche Bank AktiengesellschaftSet Target€33.00
4/13/2022Deutsche Bank AktiengesellschaftSet Target€33.00
4/12/2022Warburg ResearchSet Target€43.00
4/12/2022Royal Bank of CanadaSet Target€43.00
3/29/2022Royal Bank of CanadaSet Target€43.00
3/25/2022Deutsche Bank AktiengesellschaftSet Target€33.00
3/3/2022Royal Bank of CanadaSet Target€50.00
3/3/2022Warburg ResearchSet Target€43.00
3/2/2022Jefferies Financial GroupSet Target€55.00
2/7/2022Berenberg BankSet Target€47.00
2/7/2022Deutsche Bank AktiengesellschaftSet Target€39.00
2/4/2022Jefferies Financial GroupSet Target€55.00
2/4/2022Royal Bank of CanadaSet Target€50.00
2/4/2022Warburg ResearchSet Target€44.00
1/20/2022Berenberg BankSet Target€51.00
1/18/2022Royal Bank of CanadaSet Target€50.00
12/16/2021Royal Bank of CanadaSet Target€50.00
12/6/2021Morgan StanleySet Target€53.00
12/1/2021Deutsche Bank AktiengesellschaftSet Target€39.00
11/29/2021Jefferies Financial GroupSet Target€55.00
11/29/2021Royal Bank of CanadaSet Target€50.00
11/12/2021Deutsche Bank AktiengesellschaftSet Target€38.00
11/5/2021Warburg ResearchSet Target€47.00
10/28/2021Warburg ResearchSet Target€48.00
10/27/2021Deutsche Bank AktiengesellschaftSet Target€38.00
10/22/2021Warburg ResearchSet Target€48.00
8/18/2021Deutsche Bank AktiengesellschaftSet Target€38.00
8/17/2021Warburg ResearchSet Target€48.00
8/12/2021Deutsche Bank AktiengesellschaftSet Target€33.00
8/11/2021Warburg ResearchSet Target€40.00
6/16/2021Warburg ResearchSet TargetBuy€40.00
5/19/2021Royal Bank of CanadaSet TargetBuy€39.00
5/12/2021Deutsche Bank AktiengesellschaftSet TargetNeutral€33.00
5/11/2021Baader BankSet TargetBuy€33.00
5/11/2021Royal Bank of CanadaSet TargetBuy€39.00
5/7/2021Warburg ResearchSet TargetBuy€40.00
4/22/2021Deutsche Bank AktiengesellschaftSet TargetNeutral€33.00
4/20/2021Royal Bank of CanadaSet TargetNeutral€32.00
3/25/2021Warburg ResearchSet TargetBuy€36.00
3/25/2021Baader BankSet TargetBuy€33.00
3/22/2021Royal Bank of CanadaSet TargetNeutral€32.00
2/4/2021Baader BankSet TargetBuy€33.00
2/3/2021Warburg ResearchSet TargetBuy€36.00
1/28/2021Royal Bank of CanadaSet TargetNeutral€32.00
1/21/2021Baader BankSet TargetBuy€33.00
1/19/2021Deutsche Bank AktiengesellschaftSet TargetNeutral€29.00
1/5/2021Baader BankSet TargetBuy€28.00
12/17/2020Royal Bank of CanadaSet TargetBuy€32.00
12/17/2020Baader BankSet TargetBuy€28.00
12/11/2020Warburg ResearchSet TargetBuy€33.00
11/20/2020Royal Bank of CanadaSet TargetBuy€32.00
11/13/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
11/12/2020Baader BankSet TargetBuy€28.00
11/12/2020Royal Bank of CanadaSet TargetBuy€30.00
10/20/2020Baader BankSet TargetBuy€28.00
10/14/2020Baader BankSet TargetBuy€28.00
10/13/2020Royal Bank of CanadaSet TargetBuy€30.00
10/9/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
10/8/2020Baader BankSet TargetBuy€28.00
9/9/2020Royal Bank of CanadaSet TargetBuy€30.00
8/18/2020Baader BankSet TargetBuy€28.00
7/30/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
7/21/2020Baader BankSet TargetBuy€28.00
6/23/2020Baader BankSet TargetBuy€28.00
6/15/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
6/9/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
5/18/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
5/12/2020Deutsche Bank AktiengesellschaftSet TargetBuy€28.00
(Data available from 4/23/2020 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
9/25/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/22/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
3/24/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2025

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Evotec logo
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: €6.40
Low: €5.94
High: €6.62

50 Day Range

MA: €6.75
Low: €5.23
High: €8.90

52 Week Range

Now: €6.40
Low: €5.06
High: €21.69

Volume

2,689,547 shs

Average Volume

1,360,000 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

2.63%

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Evotec?

The following equities research analysts have issued stock ratings on Evotec in the last twelve months:
View the latest analyst ratings for EVT.

What is the current price target for Evotec?

0 Wall Street analysts have set twelve-month price targets for Evotec in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for Evotec in the next year.
View the latest price targets for EVT.

What is the current consensus analyst rating for Evotec?

Evotec currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EVT.

What other companies compete with Evotec?

Other companies that are similar to Evotec include Centrotec, CORESTATE Capital, Leoni, Euronext and Fraport. Learn More about companies similar to Evotec.

How do I contact Evotec's investor relations team?

Evotec's physical mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company's listed phone number is +49-40-560810. The official website for Evotec is www.evotec.com. Learn More about contacing Evotec investor relations.